Publications by authors named "Alessia Immacolata Cazzato"
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFBackground: Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety in Italian UC patients.
Research Design And Methods: A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score.
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
J Gastrointestin Liver Dis
December 2022
Article Synopsis
- A study was conducted to compare the efficacy and safety of four adalimumab (ADA) biosimilars in patients with inflammatory bowel disease (IBD) after they were switched from the original ADA for non-medical reasons.
- Out of 153 IBD patients, 81% maintained clinical remission during a 12-month follow-up, and there was no significant difference in outcomes among the four biosimilars.
- However, patients with ulcerative colitis (UC) experienced a higher loss of remission compared to those with Crohn's disease (CD), indicating that switching biosimilars in UC patients may require careful evaluation.
Article Synopsis
- The approval of adalimumab biosimilars has led to lower treatment costs for inflammatory bowel disease (IBD).
- A study compared the effectiveness and safety of the biosimilar GP2017 (Hyrimoz) to the original drug Humira in IBD patients in Italy.
- Results showed similar rates of clinical remission and good tolerance for both treatments, indicating that GP2017 is as effective and safe as its original counterpart.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Inflamm Bowel Dis
March 2023
Article Synopsis
- Adalimumab (ADA) biosimilars are more affordable options for treating inflammatory bowel disease (IBD), but data comparing their effectiveness and safety remains limited.* -
- A study analyzed 533 IBD patients in Italy, measuring clinical activity, remission induction, and safety across four ADA biosimilars (SB5, ABP501, GP2017, and MSB11022).* -
- Results showed high clinical remission rates (79.6% for new biologics and 81.0% for patients switched from the ADA originator) with low adverse events (6.7%), indicating similar efficacy and safety among the different biosimilars.*